Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Frequently asked questions
What sector does Oculis Holding AG Ordinary shares (OCS) operate in?
Oculis Holding AG Ordinary shares belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Oculis Holding AG Ordinary shares (OCS) current stock price?
As of the latest data, Oculis Holding AG Ordinary shares stock price is $7.95, with a previous close of $7.96. Oculis Holding AG Ordinary shares lost -$0.02 in the last trading session, representing a -0.19% loss.
What is Oculis Holding AG Ordinary shares (OCS) current market capitalization?
Oculis Holding AG Ordinary shares market cap is approximately 441.17 million.
What is Oculis Holding AG Ordinary shares (OCS) Earnings Per Share (EPS)?
The trailing EPS is -$1.67, and the forward EPS is -$1.65.
What is Oculis Holding AG Ordinary shares (OCS) EBITDA?
Oculis Holding AG Ordinary shares EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -11.72 million.
Does Oculis Holding AG Ordinary shares (OCS) pay dividends?
No. Oculis Holding AG Ordinary shares does not pay a dividend.
When is Oculis Holding AG Ordinary shares (OCS) next earnings report?
Oculis Holding AG Ordinary shares is expected to release its next earnings report on September 30, 2026.
What is Oculis Holding AG Ordinary shares (OCS) beta (volatility) score?
Oculis Holding AG Ordinary shares has a beta of 0.234, indicating lower volatility than the overall market.
